Phosphate Binder Therapy

Introduction to Phosphate Binders

Calcium carbonate appears to be the phosphate binder least likely to cause gastrointestinal side effects, including diarrhea, compared to other phosphate binders, according to the American Journal of Kidney Diseases guidelines 1
A meta-analysis indicated that gastrointestinal side effects were lowest with patients treated with calcium carbonate compared to other phosphate binders, although the effect size was small, as recommended by the American Journal of Kidney Diseases 1

The American Journal of Kidney Diseases recommends calcium carbonate as the first-line option for patients concerned about diarrhea due to its lowest incidence of GI side effects 1
For patients with hypercalcemia or at risk for vascular calcification, the American Journal of Kidney Diseases suggests avoiding calcium-based binders and considering sevelamer despite potential GI effects 2

For short-term, severe hyperphosphatemia, aluminum hydroxide can be used for 1-2 days only, but must be discontinued after short-term use due to aluminum toxicity risk, as stated by the American Journal of Kidney Diseases 1
The American Journal of Kidney Diseases recommends that phosphate binders should be taken 10-15 minutes before or during meals for optimal effect 1
Patient compliance with phosphate binder therapy ranges from 30-100%, with noncompliance often related to gastrointestinal side effects, according to the American Journal of Kidney Diseases 1

Calcium-based binders should not be used in patients with hypercalcemia, severe vascular calcification, or low parathyroid hormone levels, as recommended by the American Journal of Kidney Diseases 1
Aluminum-based binders should be limited to short-term use, avoided with concurrent use of calcium citrate, and reserved for patients with serum phosphorus >7.0 mg/dL, according to the American Journal of Kidney Diseases 1

Regular monitoring of serum calcium, phosphorus, and PTH levels is essential, as stated by the American Journal of Kidney Diseases 1
High pill burden is a significant issue with phosphate binders and can lead to poor adherence, although this fact is not directly cited, it is implied throughout the article, however, a similar fact is: patient compliance with phosphate binder therapy ranges from 30-100%, with noncompliance often related to gastrointestinal side effects, as recommended by the American Journal of Kidney Diseases 1